share_log

Additional Considerations Required While Assessing Jiangxi Sanxin MedtecLtd's (SZSE:300453) Strong Earnings

Additional Considerations Required While Assessing Jiangxi Sanxin MedtecLtd's (SZSE:300453) Strong Earnings

評估江西三鑫醫療股份有限公司(SZSE:300453)強勁收益時需要考慮的其他因素
Simply Wall St ·  2024/10/21 17:22

Jiangxi Sanxin Medtec Co.,Ltd. (SZSE:300453) announced strong profits, but the stock was stagnant. We did some digging, and we found some concerning factors in the details.

江西三鑫醫療股份有限公司(SZSE:300453)宣佈盈利較好,但股票走勢平穩。我們進行了一番調查,發現了一些細節中的令人擔憂的因素。

big
SZSE:300453 Earnings and Revenue History October 21st 2024
SZSE:300453 盈利和營業收入歷史數據 2024年10月21日

The Impact Of Unusual Items On Profit

除了稀釋之外,還應該注意的是,萬集科技在過去12個月中因不尋常項目獲得了價值人民幣3.5萬元的利潤。雖然我們希望看到利潤增加,但當這些不尋常項目對利潤做出重大貢獻時,我們會更加謹慎。我們對全球大部分上市公司的數據進行了分析,發現不尋常項目往往是一次性的。這正如我們所期望的那樣,因爲這些提升被描述爲"不尋常"。相對於其利潤而言,萬集科技在2021年12月前的不尋常項目貢獻大。因此,我們可以推斷出,這些不尋常項目正在使其財務利潤顯著增強。

For anyone who wants to understand Jiangxi Sanxin MedtecLtd's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥41m worth of unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. Which is hardly surprising, given the name. Assuming those unusual items don't show up again in the current year, we'd thus expect profit to be weaker next year (in the absence of business growth, that is).

對於想要了解江西三鑫醫療股份有限公司利潤超出法定數字的人來說,重要的是要注意,在過去十二個月的法定利潤中,有超過4100萬元人民幣的飛凡項目。雖然利潤更高總是件好事,但飛凡項目的大幅貢獻有時會消減我們的熱情。當我們分析全球絕大多數上市公司時,發現重大飛凡項目往往不會重複出現。這一點並不奇怪,鑑其名稱。假設這些飛凡項目在當前年度內不再出現,那麼我們預計明年的利潤將較弱(在沒有業務增長的情況下)。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Jiangxi Sanxin MedtecLtd.

注:我們始終建議投資者檢查資產負債表實力。單擊這裏查看我們對江西三鑫醫療股份有限公司財務狀況分析。

Our Take On Jiangxi Sanxin MedtecLtd's Profit Performance

我們對江西三鑫醫療股份有限公司的盈利表現看法

Arguably, Jiangxi Sanxin MedtecLtd's statutory earnings have been distorted by unusual items boosting profit. Therefore, it seems possible to us that Jiangxi Sanxin MedtecLtd's true underlying earnings power is actually less than its statutory profit. But at least holders can take some solace from the 52% per annum growth in EPS for the last three. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. At Simply Wall St, we found 1 warning sign for Jiangxi Sanxin MedtecLtd and we think they deserve your attention.

可以說,三鑫醫療有限公司的法定收益受到了異常項目的影響,從而提高了利潤。 因此,我們認爲三鑫醫療有限公司真正的基礎收益能力實際上可能低於其法定利潤。 但至少持有人可以從過去三年每股收益增長52%中獲得一些安慰。 當然,當涉及到分析其收益時,我們只是皮毛之下; 人們還可以考慮毛利率、預測增長和投資回報率等其他因素。 鑑於此,如果您想對該公司進行更多分析,了解相關風險是至關重要的。 在Simply Wall St,我們發現三鑫醫療有限公司有1個風險警告提示,我們認爲這值得您關注。

This note has only looked at a single factor that sheds light on the nature of Jiangxi Sanxin MedtecLtd's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

這篇筆記僅僅考慮了揭示三鑫醫療有限公司利潤性質的單一因素。 但是,如果您有能力把注意力集中在細枝末節上,總是可以發現更多。 例如,許多人認爲高淨資產回報率是有利的商業經濟的指標,而其他人則喜歡「跟着錢走」,尋找內部人員正在購買的股票。 儘管這可能需要一些研究,但您可能會發現這個收集高淨資產回報率公司的免費清單,或者具有內部重要持股股票的清單對您有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論